AVITA Medical, Inc. (RCEL)
9.88
+0.02
(+0.20%)
USD |
NASDAQ |
Sep 11, 16:00
9.87
-0.01
(-0.10%)
After-Hours: 20:00
AVITA Medical Profit Margin (Quarterly) : -35.31% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -35.31% |
| March 31, 2026 | -55.12% |
| December 31, 2025 | -65.97% |
| September 30, 2025 | -77.29% |
| June 30, 2025 | -53.86% |
| March 31, 2025 | -74.86% |
| December 31, 2024 | -62.96% |
| September 30, 2024 | -82.91% |
| June 30, 2024 | -101.3% |
| March 31, 2024 | -168.0% |
| December 31, 2023 | -49.77% |
| September 30, 2023 | -63.85% |
| Date | Value |
|---|---|
| June 30, 2023 | -88.35% |
| March 31, 2023 | -87.39% |
| December 31, 2022 | -56.62% |
| September 30, 2022 | -61.46% |
| June 30, 2022 | -75.12% |
| March 31, 2022 | -125.5% |
| June 30, 2021 | -45.79% |
| March 31, 2021 | -68.42% |
| December 31, 2020 | -110.5% |
| September 30, 2020 | -202.1% |
| June 30, 2020 | -333.1% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 47.80% |
| Iovance Biotherapeutics, Inc. | -47.64% |
| Amgen, Inc. | 23.59% |
| Editas Medicine, Inc. | -153.3% |
| Arcus Biosciences, Inc. | -222.0% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -77.60% |
| Return on Invested Capital | -148.8% |
| Gross Profit Margin (Quarterly) | 81.87% |
| Operating Margin (Quarterly) | -31.59% |
| Return on Net Operating Assets | -128.4% |